Literature DB >> 22356224

Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain.

Roberto Labianca1, Piercarlo Sarzi-Puttini, Stefano Maria Zuccaro, Paolo Cherubino, Renato Vellucci, Diego Fornasari.   

Abstract

Chronic pain is a debilitating condition that is associated with many common diseases; this places a major burden on the healthcare system. There are currently numerous analgesic agents available for the treatment of chronic pain. In general, the oral non-opioid analgesic, paracetamol, is recommended for the initial treatment of mild to moderate pain. Therapeutic doses of paracetamol do not appear to result in hepatotoxicity, although overdose may lead to acute liver failure. Current data suggest that paracetamol has acceptable gastrointestinal tolerability. Another class of non-opioid analgesic with confirmed efficacy for the treatment of chronic mild to moderate pain are non-steroidal anti-inflammatory drugs (NSAIDs), although this efficacy is offset by the potential of adverse gastrointestinal events. In particular, non-selective NSAIDs, also known as cyclooxygenase (COX) inhibitors, carry an increased risk of serious upper gastrointestinal complications, including ulcers, perforation and bleeding. The introduction of COX-2 inhibitors provided a NSAID-based option with improved gastrointestinal safety, but increased risk of cardiovascular effects. Opioids are powerful analgesic agents used to treat moderate to severe chronic pain. However, treatment with opioids is associated with a number of common adverse effects, including constipation, nausea or vomiting, pruritus, somnolence or cognitive impairment, dry mouth, tolerance or dependence and urinary retention. Although there are multiple strategies in place to manage adverse events that arise from both non-opioid and opioid analgesic therapy, a better understanding of the mechanisms involved in the development of specific drug-related adverse effects is required along with proper prescribing practices and adequate physician/patient education. Balanced against the adverse effects of pain management medications, there is a need to be mindful of the widespread, often serious, adverse consequences of poorly managed pain itself.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22356224     DOI: 10.2165/11630080-000000000-00000

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  44 in total

1.  Prescription Opioid Use and Satisfaction With Care Among Adults With Musculoskeletal Conditions.

Authors:  Brian D Sites; Jordon Harrison; Michael D Herrick; Melissa M Masaracchia; Michael L Beach; Matthew A Davis
Journal:  Ann Fam Med       Date:  2018-01       Impact factor: 5.166

Review 2.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

Review 3.  Molecular and cellular mechanisms that initiate pain and itch.

Authors:  Jialie Luo; Jing Feng; Shenbin Liu; Edgar T Walters; Hongzhen Hu
Journal:  Cell Mol Life Sci       Date:  2015-04-18       Impact factor: 9.261

Review 4.  Use of opioids for treatment of osteoporotic pain.

Authors:  Renato Vellucci; Rocco Domenico Mediati; Giovanna Ballerini
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

5.  Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe.

Authors:  Karima Hider-Mlynarz; Philippe Cavalié; Patrick Maison
Journal:  Br J Clin Pharmacol       Date:  2018-04-02       Impact factor: 4.335

Review 6.  [Injection treatment with hyaluronic acid].

Authors:  J Jerosch
Journal:  Z Rheumatol       Date:  2015-11       Impact factor: 1.372

7.  Analgesic Properties of Opioid/NK1 Multitarget Ligands with Distinct in Vitro Profiles in Naive and Chronic Constriction Injury Mice.

Authors:  Joanna Starnowska; Roberto Costante; Karel Guillemyn; Katarzyna Popiolek-Barczyk; Nga N Chung; Carole Lemieux; Attila Keresztes; Joost Van Duppen; Adriano Mollica; John Streicher; Jozef Vanden Broeck; Peter W Schiller; Dirk Tourwé; Joanna Mika; Steven Ballet; Barbara Przewlocka
Journal:  ACS Chem Neurosci       Date:  2017-07-26       Impact factor: 4.418

8.  Opioid switching and variability in response in pain cancer patients.

Authors:  O Corli; A Roberto; N Corsi; F Galli; M Pizzuto
Journal:  Support Care Cancer       Date:  2018-10-24       Impact factor: 3.603

Review 9.  Cancer-induced oxidative stress and pain.

Authors:  Mina G Nashed; Matthew D Balenko; Gurmit Singh
Journal:  Curr Pain Headache Rep       Date:  2014-01

10.  Pain management perceptions among prescription opioid dependent individuals.

Authors:  Jenna L McCauley; Mary Ashley Mercer; Kelly S Barth; Kathleen T Brady; Sudie E Back
Journal:  Drug Alcohol Depend       Date:  2014-06-25       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.